Brief: Starpharma Says SPL7013 Showed Potent Antiviral Activity Against Omicron Variant
01/03/2022 01:15
March 1 (Reuters) - Starpharma Holdings Ltd SPL.AX :
* STARPHARMA HOLDINGS LTD - SPL7013 SHOWED POTENT ANTIVIRAL
ACTIVITY AND WAS VIRUCIDAL AGAINST OMICRON VARIANT
* STARPHARMA - ANTIVIRAL AGENT IN VIRALEZE ANTIVIRAL NASAL
SPRAY,
SPL7013, ACHIEVED >99.5% REDUCTION OF VIRUS INFECTIVITY AGAINST
OMICRON VARIANT
Source text for Eikon: ID:nASX8l6MDR
Further company coverage: SPL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Starpharma Holdings
See all newsBrief: Starpharma Increases Stake In Petalion To 66% Securing Majority Ownership
Brief: Starpharma Seeks Trading Halt
Brief: Starpharma Holdings Appoints Russell Basser As Chair
Brief: Starpharma Says Fully Underwritten Entitlement Offer To Raise A$32 MLN
Australia's Starpharma slumps to 1-1/2-month low on discounted fund raising